FDA approves relacorilant for resistant ovarian cancer
Silver Spring, Md. — The U.S. Food and Drug Administration has approved relacorilant (Lifyorli) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer…